Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Developments in gene therapy for muscular dystrophy.

D Hartigan-O'Connor1, J S Chamberlain

  • 1Program in Cellular and Molecular Biology, University of Michigan Medical School, Ann Arbor, Michigan 48109-0618, USA.

Microscopy Research and Technique
|February 19, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Heparin-binding correlates with increased efficiency of AAV1- and AAV6-mediated transduction of striated muscle, but negatively impacts CNS transduction.

Gene therapy·2012
Same author

Microarchitecture is severely compromised but motor protein function is preserved in dystrophic mdx skeletal muscle.

Biophysical journal·2010
Same author

Unloaded speed of shortening in voltage-clamped intact skeletal muscle fibers from wt, mdx, and transgenic minidystrophin mice using a novel high-speed acquisition system.

Biophysical journal·2008
Same author

Gene therapy for Duchenne muscular dystrophy: AAV leads the way.

Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology·2006
Same author

Stable transduction of myogenic cells with lentiviral vectors expressing a minidystrophin.

Gene therapy·2005
Same author

Characterization of ARC, apoptosis repressor interacting with CARD, in normal and dystrophin-deficient skeletal muscle.

Human molecular genetics·2003

Gene therapy for muscular dystrophy (MD) faces challenges with gene delivery and immune response. Advances in adenovirus (Ad) and adeno-associated virus (AAV) vectors show promise for overcoming these hurdles in MD treatment.

Area of Science:

  • Biomedical research
  • Molecular biology
  • Genetics

Background:

  • Gene therapy for muscular dystrophy (MD) is complex due to large gene sizes, extensive muscle tissue, and potential immune reactions.
  • Developing effective gene transfer vectors is crucial for successful MD gene therapy.

Purpose of the Study:

  • To review recent advances in gene transfer vectors for muscular dystrophy treatment.
  • To assess the potential of modified adenovirus (Ad) and adeno-associated virus (AAV) vectors in overcoming MD gene therapy challenges.

Main Methods:

  • Modification of adenovirus (Ad) vectors to enhance capacity and reduce immunogenicity.
  • Utilizing gutted Ad vectors for delivery of full-length dystrophin cDNA.
  • Employing muscle-specific promoters for controlled gene expression.

Related Experiment Videos

  • Investigating adeno-associated virus (AAV) vectors for delivering small MD genes and sarcoglycan genes.

    • Main Results:

    • Gutted Ad vectors successfully delivered dystrophin cDNA to muscle tissue in mdx mice without significant immune response.
    • Adeno-associated virus (AAV) vectors demonstrated the ability to deliver small genes to muscle, potentially enabling long-term expression.
    • AAV vectors have been used to deliver sarcoglycan genes to entire muscle groups.

    Conclusions:

    • Significant progress has been made in developing gene transfer vectors for MD.
    • Barriers to effective gene therapy for muscular dystrophy, including immune response and gene delivery, appear surmountable with current vector technologies.